Abstract
Tumor immunology is a critical area of cancer research that focuses on the interplay between the immune system and tumor cells. The immune system has the ability to recognize and eliminate cancer cells through various immune cells, such as cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. However, tumors have developed sophisticated mechanisms to evade immune detection, such as the loss of tumor antigen expression, recruitment of immunosuppressive cells, and upregulation of immune checkpoints. These immune evasion strategies allow tumors to grow uncontrollably and metastasize. Immunotherapy has emerged as a promising treatment modality that harnesses the power of the immune system to fight cancer. Key strategies include immune checkpoint inhibitors, which block inhibitory receptors like programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4, and adoptive cell therapies, which involve the transfer of tumor-specific T cells or NK cells into patients. Additionally, monoclonal antibodies and cancer vaccines are being explored to directly target tumor cells and enhance immune responses. Despite the success of these therapies, challenges such as tumor heterogeneity, resistance to treatment, and immune-related adverse effects persist.